The MiSeqDx instrument is the first FDA-cleared <i>in vitro</i> diagnostic (IVD) next-generation sequencing (NGS) system.
MiSeqDxアプリケーションには、嚢胞性線維症検査、結腸がん評価、NGSを用いたアッセイ開発のためにFDA認可／FDA承認を受けたアッセイが含まれます。
The MiSeqDx Cystic Fibrosis System uses next-generation targeted sequencing to identify mutations within the CFTR gene. It is the first and only FDA-cleared in vitro diagnostic (IVD) NGS platform. *日本未発売